Delcath Systems (NASDAQ:DCTH - Get Free Report) had its price target increased by HC Wainwright from $22.00 to $24.00 in a research note issued to investors on Friday, MarketBeat Ratings reports. The firm presently has a "buy" rating on the stock. HC Wainwright's target price would suggest a potential upside of 103.39% from the company's current price. HC Wainwright also issued estimates for Delcath Systems' FY2029 earnings at $1.58 EPS.
Separately, Craig Hallum raised their target price on Delcath Systems from $18.00 to $21.00 and gave the stock a "buy" rating in a research note on Friday, January 17th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $22.75.
View Our Latest Stock Analysis on Delcath Systems
Delcath Systems Price Performance
NASDAQ DCTH traded down $0.01 on Friday, reaching $11.80. The company had a trading volume of 283,605 shares, compared to its average volume of 330,100. The firm has a market cap of $377.29 million, a price-to-earnings ratio of -8.74 and a beta of 0.82. Delcath Systems has a fifty-two week low of $3.70 and a fifty-two week high of $16.97. The business has a 50 day moving average of $14.42 and a two-hundred day moving average of $11.75.
Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The company had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.96 million. During the same quarter last year, the business earned ($0.48) earnings per share. As a group, research analysts predict that Delcath Systems will post -0.79 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Delcath Systems
Institutional investors have recently modified their holdings of the company. Quarry LP bought a new stake in Delcath Systems during the 4th quarter valued at $34,000. Quantbot Technologies LP bought a new stake in shares of Delcath Systems during the fourth quarter worth about $66,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Delcath Systems in the 3rd quarter worth about $102,000. Barclays PLC bought a new position in Delcath Systems in the 3rd quarter valued at about $104,000. Finally, Jane Street Group LLC bought a new position in Delcath Systems in the 3rd quarter valued at about $110,000. 61.12% of the stock is owned by institutional investors and hedge funds.
About Delcath Systems
(
Get Free Report)
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Featured Articles
Before you consider Delcath Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Delcath Systems wasn't on the list.
While Delcath Systems currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
